Table 2 The clinicopatholgical characteristics of patients included in POPLAR and OAK trials.
From: Pan-cancer analysis of SETD2 mutation and its association with the efficacy of immunotherapy
SETD2 mutant | SETD2 nonmutant | P | |
|---|---|---|---|
Number of patients | 24 | 545 | |
Age(median, range, year) | 63(39–80) | 63(33–82) | 0.34 |
Race (White/Other, %) | 83/17 | 72/28 | 0.11 |
Sex (male/female, %) | 63/37 | 62/38 | 0.49 |
Smoking status (current/former/never, %) | 21/71/8 | 14/66/20 | 0.07 |
ECOG performance status (1/0, %) | 67/33 | 64/36 | 0.40 |
Subtype (squamous/non-squamous, %) | 38/62 | 28/72 | 0.15 |
Line of treatment (second/third, %) | 63/37 | 73/27 | 0.13 |
Mean diameter of target lesion | 78.88 | 77.52 | 0.45 |
Mean number of metastatic sites | 3.04 | 2.91 | 0.33 |
KRAS mutant status (positive/negative/unknown, %) | 0/21/79 | 7/22/71 | 0.11 |
EGFR mutant status (positive/negative/unknown, %) | 8/63/29 | 9/69/22 | 0.50 |
EML4-ALK mutant status (positive/negative/unknown, %) | 0/63/37 | 0/49/51 | 0.37 |
PD-L1 expressiona (positive/negative/unknown, %) | 58/13/29 | 42/32/26 | 0.02 |
TMB (mean ± SE) | 17.13 ± 2.32 | 10.65 ± 0.45 | 0.001 |
